nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.319	0.691	CbGbCtD
Sulindac—PTGS2—amyotrophic lateral sclerosis	0.269	1	CbGaD
Sulindac—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.143	0.309	CbGbCtD
Sulindac—AKR1B1—sciatic nerve—amyotrophic lateral sclerosis	0.0221	0.316	CbGeAlD
Sulindac—AKR1B1—peripheral nervous system—amyotrophic lateral sclerosis	0.00848	0.121	CbGeAlD
Sulindac—Disseminated intravascular coagulation—Riluzole—amyotrophic lateral sclerosis	0.00566	0.0539	CcSEcCtD
Sulindac—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00352	0.0335	CcSEcCtD
Sulindac—AKR1B1—embryo—amyotrophic lateral sclerosis	0.0031	0.0442	CbGeAlD
Sulindac—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00308	0.0294	CcSEcCtD
Sulindac—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00271	0.0258	CcSEcCtD
Sulindac—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00271	0.0258	CcSEcCtD
Sulindac—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00264	0.0252	CcSEcCtD
Sulindac—PTGDR2—cerebellum—amyotrophic lateral sclerosis	0.00263	0.0376	CbGeAlD
Sulindac—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00251	0.024	CcSEcCtD
Sulindac—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00249	0.0238	CcSEcCtD
Sulindac—MAPK3—embryo—amyotrophic lateral sclerosis	0.00224	0.032	CbGeAlD
Sulindac—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00219	0.0209	CcSEcCtD
Sulindac—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00215	0.0205	CcSEcCtD
Sulindac—PTGDR2—brain—amyotrophic lateral sclerosis	0.00214	0.0305	CbGeAlD
Sulindac—PTGS2—hindlimb—amyotrophic lateral sclerosis	0.00205	0.0292	CbGeAlD
Sulindac—AKR1B1—medulla oblongata—amyotrophic lateral sclerosis	0.00198	0.0282	CbGeAlD
Sulindac—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00195	0.0186	CcSEcCtD
Sulindac—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0181	CcSEcCtD
Sulindac—Coma—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0176	CcSEcCtD
Sulindac—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00183	0.0174	CcSEcCtD
Sulindac—AKR1B1—spinal cord—amyotrophic lateral sclerosis	0.00176	0.0252	CbGeAlD
Sulindac—PTGS2—appendage—amyotrophic lateral sclerosis	0.00176	0.0251	CbGeAlD
Sulindac—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0159	CcSEcCtD
Sulindac—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00164	0.0156	CcSEcCtD
Sulindac—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00162	0.0154	CcSEcCtD
Sulindac—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00155	0.0148	CcSEcCtD
Sulindac—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0145	CcSEcCtD
Sulindac—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0144	CcSEcCtD
Sulindac—AKR1B1—nervous system—amyotrophic lateral sclerosis	0.00149	0.0212	CbGeAlD
Sulindac—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00147	0.014	CcSEcCtD
Sulindac—MAPK3—medulla oblongata—amyotrophic lateral sclerosis	0.00143	0.0205	CbGeAlD
Sulindac—AKR1B1—central nervous system—amyotrophic lateral sclerosis	0.00143	0.0204	CbGeAlD
Sulindac—AKR1B1—cerebellum—amyotrophic lateral sclerosis	0.0014	0.02	CbGeAlD
Sulindac—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0124	CcSEcCtD
Sulindac—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00129	0.0123	CcSEcCtD
Sulindac—MAPK3—spinal cord—amyotrophic lateral sclerosis	0.00128	0.0183	CbGeAlD
Sulindac—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0118	CcSEcCtD
Sulindac—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.0012	0.0115	CcSEcCtD
Sulindac—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0113	CcSEcCtD
Sulindac—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0113	CcSEcCtD
Sulindac—PPARD—nervous system—amyotrophic lateral sclerosis	0.00117	0.0167	CbGeAlD
Sulindac—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00116	0.011	CcSEcCtD
Sulindac—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00114	0.0108	CcSEcCtD
Sulindac—AKR1B1—brain—amyotrophic lateral sclerosis	0.00114	0.0162	CbGeAlD
Sulindac—Depression—Riluzole—amyotrophic lateral sclerosis	0.00113	0.0107	CcSEcCtD
Sulindac—PPARD—central nervous system—amyotrophic lateral sclerosis	0.00113	0.0161	CbGeAlD
Sulindac—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00111	0.0106	CcSEcCtD
Sulindac—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0105	CcSEcCtD
Sulindac—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0105	CcSEcCtD
Sulindac—PPARD—cerebellum—amyotrophic lateral sclerosis	0.0011	0.0157	CbGeAlD
Sulindac—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00108	0.0103	CcSEcCtD
Sulindac—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00108	0.0103	CcSEcCtD
Sulindac—MAPK3—nervous system—amyotrophic lateral sclerosis	0.00108	0.0154	CbGeAlD
Sulindac—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0102	CcSEcCtD
Sulindac—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00105	0.0101	CcSEcCtD
Sulindac—MAPK3—central nervous system—amyotrophic lateral sclerosis	0.00104	0.0148	CbGeAlD
Sulindac—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00967	CcSEcCtD
Sulindac—MAPK3—cerebellum—amyotrophic lateral sclerosis	0.00101	0.0145	CbGeAlD
Sulindac—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00914	CcSEcCtD
Sulindac—Chills—Riluzole—amyotrophic lateral sclerosis	0.00091	0.00868	CcSEcCtD
Sulindac—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000906	0.00864	CcSEcCtD
Sulindac—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000896	0.00855	CcSEcCtD
Sulindac—PPARD—brain—amyotrophic lateral sclerosis	0.000893	0.0128	CbGeAlD
Sulindac—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00087	0.0083	CcSEcCtD
Sulindac—Tension—Riluzole—amyotrophic lateral sclerosis	0.000867	0.00826	CcSEcCtD
Sulindac—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000865	0.00825	CcSEcCtD
Sulindac—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000858	0.00818	CcSEcCtD
Sulindac—MAPK3—brain—amyotrophic lateral sclerosis	0.000823	0.0118	CbGeAlD
Sulindac—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000819	0.00781	CcSEcCtD
Sulindac—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000816	0.00778	CcSEcCtD
Sulindac—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000807	0.00769	CcSEcCtD
Sulindac—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000796	0.00759	CcSEcCtD
Sulindac—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000793	0.00756	CcSEcCtD
Sulindac—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000792	0.00755	CcSEcCtD
Sulindac—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000791	0.00754	CcSEcCtD
Sulindac—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00744	CcSEcCtD
Sulindac—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000776	0.0074	CcSEcCtD
Sulindac—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000765	0.00729	CcSEcCtD
Sulindac—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000762	0.00727	CcSEcCtD
Sulindac—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000752	0.00717	CcSEcCtD
Sulindac—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000752	0.00717	CcSEcCtD
Sulindac—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000752	0.00717	CcSEcCtD
Sulindac—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000743	0.00708	CcSEcCtD
Sulindac—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000721	0.00687	CcSEcCtD
Sulindac—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000721	0.00687	CcSEcCtD
Sulindac—Shock—Riluzole—amyotrophic lateral sclerosis	0.000709	0.00676	CcSEcCtD
Sulindac—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000706	0.00673	CcSEcCtD
Sulindac—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000703	0.00671	CcSEcCtD
Sulindac—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000697	0.00664	CcSEcCtD
Sulindac—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000687	0.00655	CcSEcCtD
Sulindac—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000674	0.00642	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000657	0.00626	CcSEcCtD
Sulindac—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000652	0.00621	CcSEcCtD
Sulindac—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000647	0.00617	CcSEcCtD
Sulindac—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000643	0.00613	CcSEcCtD
Sulindac—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000641	0.00611	CcSEcCtD
Sulindac—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000634	0.00605	CcSEcCtD
Sulindac—SLC22A6—brain—amyotrophic lateral sclerosis	0.00063	0.00899	CbGeAlD
Sulindac—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000627	0.00597	CcSEcCtD
Sulindac—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000621	0.00592	CcSEcCtD
Sulindac—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000616	0.00588	CcSEcCtD
Sulindac—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000594	0.00566	CcSEcCtD
Sulindac—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000589	0.00562	CcSEcCtD
Sulindac—PTGS2—embryo—amyotrophic lateral sclerosis	0.000583	0.00832	CbGeAlD
Sulindac—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000573	0.00546	CcSEcCtD
Sulindac—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00057	0.00543	CcSEcCtD
Sulindac—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000531	0.00506	CcSEcCtD
Sulindac—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000517	0.00493	CcSEcCtD
Sulindac—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00051	0.00486	CcSEcCtD
Sulindac—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000493	0.0047	CcSEcCtD
Sulindac—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000477	0.00454	CcSEcCtD
Sulindac—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000458	0.00437	CcSEcCtD
Sulindac—Rash—Riluzole—amyotrophic lateral sclerosis	0.000454	0.00433	CcSEcCtD
Sulindac—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000454	0.00433	CcSEcCtD
Sulindac—Headache—Riluzole—amyotrophic lateral sclerosis	0.000452	0.0043	CcSEcCtD
Sulindac—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000428	0.00408	CcSEcCtD
Sulindac—ALB—brain—amyotrophic lateral sclerosis	0.000393	0.00561	CbGeAlD
Sulindac—PTGS2—medulla oblongata—amyotrophic lateral sclerosis	0.000372	0.00532	CbGeAlD
Sulindac—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.000347	0.00496	CbGeAlD
Sulindac—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000333	0.00476	CbGeAlD
Sulindac—PTGS2—spinal cord—amyotrophic lateral sclerosis	0.000332	0.00474	CbGeAlD
Sulindac—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.000321	0.00458	CbGeAlD
Sulindac—PTGS1—nervous system—amyotrophic lateral sclerosis	0.000293	0.00418	CbGeAlD
Sulindac—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000282	0.00402	CbGeAlD
Sulindac—PTGS2—nervous system—amyotrophic lateral sclerosis	0.00028	0.004	CbGeAlD
Sulindac—PTGS2—central nervous system—amyotrophic lateral sclerosis	0.000269	0.00385	CbGeAlD
Sulindac—PTGS2—cerebellum—amyotrophic lateral sclerosis	0.000263	0.00376	CbGeAlD
Sulindac—CYP1A1—brain—amyotrophic lateral sclerosis	0.000255	0.00364	CbGeAlD
Sulindac—PTGS1—brain—amyotrophic lateral sclerosis	0.000224	0.0032	CbGeAlD
Sulindac—PTGS2—brain—amyotrophic lateral sclerosis	0.000214	0.00305	CbGeAlD
Sulindac—PTGS1—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	7.62e-05	0.00081	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	7.61e-05	0.000808	CbGpPWpGaD
Sulindac—MAPK3—Rac1/Pak1/p38/MMP-2 pathway—TP53—amyotrophic lateral sclerosis	7.53e-05	0.000801	CbGpPWpGaD
Sulindac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	7.53e-05	0.0008	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	7.48e-05	0.000795	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	7.47e-05	0.000794	CbGpPWpGaD
Sulindac—ALB—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	7.39e-05	0.000786	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.32e-05	0.000778	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—FUS—amyotrophic lateral sclerosis	7.3e-05	0.000776	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	7.23e-05	0.000768	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	7.23e-05	0.000768	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	7.18e-05	0.000763	CbGpPWpGaD
Sulindac—PPARD—Metabolism—CHAT—amyotrophic lateral sclerosis	7.16e-05	0.000761	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	7.11e-05	0.000756	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	7.07e-05	0.000751	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	7.06e-05	0.00075	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.87e-05	0.00073	CbGpPWpGaD
Sulindac—MAPK3—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	6.86e-05	0.000729	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	6.86e-05	0.000729	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	6.65e-05	0.000707	CbGpPWpGaD
Sulindac—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	6.61e-05	0.000703	CbGpPWpGaD
Sulindac—MAPK3—Alzheimers Disease—TP53—amyotrophic lateral sclerosis	6.6e-05	0.000702	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	6.6e-05	0.000702	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.6e-05	0.000701	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.6e-05	0.000701	CbGpPWpGaD
Sulindac—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	6.59e-05	0.0007	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.54e-05	0.000695	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.53e-05	0.000695	CbGpPWpGaD
Sulindac—MAPK3—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	6.47e-05	0.000688	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.44e-05	0.000685	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	6.44e-05	0.000685	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways in Glioblastoma—TP53—amyotrophic lateral sclerosis	6.41e-05	0.000681	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—TP53—amyotrophic lateral sclerosis	6.41e-05	0.000681	CbGpPWpGaD
Sulindac—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	6.37e-05	0.000677	CbGpPWpGaD
Sulindac—MAPK3—Disease—CHMP2B—amyotrophic lateral sclerosis	6.37e-05	0.000677	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	6.37e-05	0.000677	CbGpPWpGaD
Sulindac—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	6.25e-05	0.000665	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.15e-05	0.000654	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	6.12e-05	0.000651	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	6.09e-05	0.000647	CbGpPWpGaD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	6.07e-05	0.000645	CbGpPWpGaD
Sulindac—CYP1A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.07e-05	0.000645	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	6.05e-05	0.000643	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.03e-05	0.000641	CbGpPWpGaD
Sulindac—CYP1A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.98e-05	0.000636	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—RARA—amyotrophic lateral sclerosis	5.95e-05	0.000632	CbGpPWpGaD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—TP53—amyotrophic lateral sclerosis	5.9e-05	0.000627	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	5.87e-05	0.000624	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	5.78e-05	0.000614	CbGpPWpGaD
Sulindac—MAPK3—Disease—PLB1—amyotrophic lateral sclerosis	5.76e-05	0.000612	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	5.75e-05	0.000612	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.72e-05	0.000608	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	5.66e-05	0.000601	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	5.63e-05	0.000599	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.61e-05	0.000596	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.6e-05	0.000595	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.51e-05	0.000585	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	5.49e-05	0.000583	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	5.47e-05	0.000582	CbGpPWpGaD
Sulindac—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	5.38e-05	0.000572	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	5.32e-05	0.000565	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.27e-05	0.00056	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.26e-05	0.000559	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	5.24e-05	0.000557	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	5.24e-05	0.000557	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—ATF1—amyotrophic lateral sclerosis	5.23e-05	0.000556	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.21e-05	0.000554	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	5.18e-05	0.00055	CbGpPWpGaD
Sulindac—MAPK3—Disease—VCP—amyotrophic lateral sclerosis	5.13e-05	0.000546	CbGpPWpGaD
Sulindac—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	5.1e-05	0.000542	CbGpPWpGaD
Sulindac—MAPK3—Immune System—DCTN1—amyotrophic lateral sclerosis	5.09e-05	0.000541	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	5.08e-05	0.00054	CbGpPWpGaD
Sulindac—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	5e-05	0.000531	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CASP9—amyotrophic lateral sclerosis	4.98e-05	0.00053	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—SOD1—amyotrophic lateral sclerosis	4.97e-05	0.000528	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	4.94e-05	0.000525	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	4.9e-05	0.00052	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.88e-05	0.000519	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	4.79e-05	0.000509	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	4.79e-05	0.000509	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	4.77e-05	0.000507	CbGpPWpGaD
Sulindac—MAPK3—Oxidative Stress Induced Senescence—TP53—amyotrophic lateral sclerosis	4.76e-05	0.000506	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.65e-05	0.000494	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.65e-05	0.000494	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.65e-05	0.000494	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	4.64e-05	0.000493	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	4.53e-05	0.000482	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.48e-05	0.000476	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	4.45e-05	0.000473	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.45e-05	0.000473	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	4.44e-05	0.000472	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	4.42e-05	0.00047	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.33e-05	0.000461	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.33e-05	0.00046	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.31e-05	0.000458	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	4.27e-05	0.000453	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	4.25e-05	0.000452	CbGpPWpGaD
Sulindac—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	4.24e-05	0.00045	CbGpPWpGaD
Sulindac—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	4.24e-05	0.00045	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	4.2e-05	0.000446	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.19e-05	0.000445	CbGpPWpGaD
Sulindac—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	4.16e-05	0.000442	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	4.16e-05	0.000442	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	4.03e-05	0.000429	CbGpPWpGaD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	3.97e-05	0.000421	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.95e-05	0.00042	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.95e-05	0.00042	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	3.93e-05	0.000417	CbGpPWpGaD
Sulindac—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	3.87e-05	0.000412	CbGpPWpGaD
Sulindac—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.87e-05	0.000411	CbGpPWpGaD
Sulindac—PPARD—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.85e-05	0.000409	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	3.84e-05	0.000408	CbGpPWpGaD
Sulindac—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.81e-05	0.000405	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.79e-05	0.000403	CbGpPWpGaD
Sulindac—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	3.79e-05	0.000403	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	3.79e-05	0.000402	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.76e-05	0.000399	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.76e-05	0.000399	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.72e-05	0.000395	CbGpPWpGaD
Sulindac—MAPK3—Disease—CST3—amyotrophic lateral sclerosis	3.69e-05	0.000392	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	3.68e-05	0.000391	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	3.67e-05	0.00039	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.65e-05	0.000387	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.61e-05	0.000384	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	3.61e-05	0.000384	CbGpPWpGaD
Sulindac—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.6e-05	0.000383	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.6e-05	0.000382	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.58e-05	0.00038	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—C3—amyotrophic lateral sclerosis	3.54e-05	0.000377	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.54e-05	0.000376	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.48e-05	0.00037	CbGpPWpGaD
Sulindac—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	3.43e-05	0.000364	CbGpPWpGaD
Sulindac—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	3.39e-05	0.00036	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	3.36e-05	0.000357	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3.35e-05	0.000356	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	3.34e-05	0.000355	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—VEGFA—amyotrophic lateral sclerosis	3.33e-05	0.000354	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—amyotrophic lateral sclerosis	3.33e-05	0.000354	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.26e-05	0.000346	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SQSTM1—amyotrophic lateral sclerosis	3.25e-05	0.000345	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MMP9—amyotrophic lateral sclerosis	3.15e-05	0.000334	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.09e-05	0.000329	CbGpPWpGaD
Sulindac—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	3.06e-05	0.000326	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.06e-05	0.000325	CbGpPWpGaD
Sulindac—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	3.05e-05	0.000325	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ATF1—amyotrophic lateral sclerosis	3.05e-05	0.000324	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.04e-05	0.000323	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IGF1—amyotrophic lateral sclerosis	3.03e-05	0.000322	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.02e-05	0.000321	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.96e-05	0.000315	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.96e-05	0.000315	CbGpPWpGaD
Sulindac—PPARD—Metabolism—APOE—amyotrophic lateral sclerosis	2.91e-05	0.000309	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CASP9—amyotrophic lateral sclerosis	2.9e-05	0.000308	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.87e-05	0.000305	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	2.85e-05	0.000303	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	2.83e-05	0.0003	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.83e-05	0.0003	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.76e-05	0.000294	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.75e-05	0.000293	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.74e-05	0.000291	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.71e-05	0.000288	CbGpPWpGaD
Sulindac—MAPK3—Disease—CASP9—amyotrophic lateral sclerosis	2.68e-05	0.000285	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	2.65e-05	0.000281	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.6e-05	0.000277	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.56e-05	0.000273	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.56e-05	0.000272	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.55e-05	0.000271	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.52e-05	0.000268	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	2.52e-05	0.000267	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.5e-05	0.000266	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ERBB4—amyotrophic lateral sclerosis	2.48e-05	0.000264	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.41e-05	0.000256	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	2.39e-05	0.000254	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.37e-05	0.000252	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	2.35e-05	0.00025	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.34e-05	0.000248	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD40LG—amyotrophic lateral sclerosis	2.34e-05	0.000248	CbGpPWpGaD
Sulindac—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	2.32e-05	0.000247	CbGpPWpGaD
Sulindac—MAPK3—Disease—ERBB4—amyotrophic lateral sclerosis	2.29e-05	0.000244	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.26e-05	0.00024	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.25e-05	0.000239	CbGpPWpGaD
Sulindac—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	2.19e-05	0.000233	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.17e-05	0.000231	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	2.14e-05	0.000228	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.14e-05	0.000228	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	2.14e-05	0.000228	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.14e-05	0.000227	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.1e-05	0.000223	CbGpPWpGaD
Sulindac—MAPK3—Immune System—C3—amyotrophic lateral sclerosis	2.06e-05	0.000219	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.02e-05	0.000214	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.99e-05	0.000212	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.98e-05	0.000211	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.98e-05	0.00021	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.97e-05	0.000209	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.95e-05	0.000207	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.94e-05	0.000206	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.93e-05	0.000205	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.88e-05	0.000199	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	1.85e-05	0.000196	CbGpPWpGaD
Sulindac—MAPK3—Disease—APOE—amyotrophic lateral sclerosis	1.77e-05	0.000189	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.77e-05	0.000188	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.76e-05	0.000187	CbGpPWpGaD
Sulindac—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	1.76e-05	0.000187	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.71e-05	0.000182	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.62e-05	0.000173	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.61e-05	0.000171	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.61e-05	0.000171	CbGpPWpGaD
Sulindac—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	1.59e-05	0.000169	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.51e-05	0.00016	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.5e-05	0.000159	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—amyotrophic lateral sclerosis	1.49e-05	0.000159	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.47e-05	0.000156	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.46e-05	0.000155	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.41e-05	0.00015	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.36e-05	0.000145	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	1.36e-05	0.000145	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.35e-05	0.000144	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.33e-05	0.000142	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.24e-05	0.000132	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.23e-05	0.000131	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—amyotrophic lateral sclerosis	1.22e-05	0.000129	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.21e-05	0.000128	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.17e-05	0.000124	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.12e-05	0.000119	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	1.11e-05	0.000118	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.1e-05	0.000117	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.07e-05	0.000114	CbGpPWpGaD
Sulindac—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	1.06e-05	0.000112	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.04e-05	0.00011	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.03e-05	0.000109	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.53e-06	0.000101	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	9.52e-06	0.000101	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.46e-06	0.0001	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	8.84e-06	9.39e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.69e-06	9.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.9e-06	8.4e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	7.84e-06	8.34e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.69e-06	8.18e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.63e-06	8.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.47e-06	7.94e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	7.19e-06	7.64e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	7.15e-06	7.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.71e-06	7.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.61e-06	7.03e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.08e-06	6.46e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.37e-06	5.71e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.07e-06	5.39e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	5e-06	5.31e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.9e-06	5.21e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.43e-06	3.64e-05	CbGpPWpGaD
